Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company's pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. has a clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone972-3765-8585
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$710,000.00
Profitability
Miscellaneous
Employees101
OptionableOptionable
Compugen (NASDAQ:CGEN) Frequently Asked Questions
What is Compugen's stock symbol?
Compugen trades on the NASDAQ under the ticker symbol "CGEN."
How were Compugen's earnings last quarter?
Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.07. The biotechnology company earned $7.80 million during the quarter, compared to analyst estimates of $7.80 million. View Compugen's Earnings History.
When is Compugen's next earnings date?
What price target have analysts set for CGEN?
2 equities research analysts have issued 12 month target prices for Compugen's stock. Their predictions range from $9.00 to $9.00. On average, they anticipate Compugen's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 186.6% from the stock's current price. View Analyst Price Targets for Compugen.
What is the consensus analysts' recommendation for Compugen?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Compugen.
Has Compugen been receiving favorable news coverage?
News coverage about CGEN stock has trended negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Compugen earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the stock's share price in the next few days.
Who are some of Compugen's key competitors?
Some companies that are related to Compugen include Adaptimmune Therapeutics (ADAP), Gritstone Oncology (GRTS), DBV TECHNOLOGIE/S (DBVT), PDL BioPharma (PDLI), Mesoblast (MESO), Scholar Rock (SRRK), Agenus (AGEN), CASI Pharmaceuticals (CASI), Nightstar Therapeutics (NITE), Krystal Biotech (KRYS), Avrobio (AVRO), Replimune Group (REPL), Cellular Biomedicine Group (CBMG), MeiraGTx (MGTX) and Voyager Therapeutics (VYGR).
Who are Compugen's key executives?
Compugen's management team includes the folowing people:
- Dr. Anat Cohen-Dayag, CEO, Pres & Director (Age 52)
- Mr. Ari Krashin, Chief Financial & Operating Officer (Age 46)
- Mr. Kirk A. Christoffersen, Sr. VP of Corp. & Bus. Devel. (Age 50)
- Dr. Zurit Levine, VP of Research & Discovery (Age 51)
- Dr. John J. Hunter Ph.D., VP of Antibody R&D (Age 56)
Who are Compugen's major shareholders?
Compugen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Cornerstone Investment Partners LLC (0.03%).
Which major investors are buying Compugen stock?
CGEN stock was bought by a variety of institutional investors in the last quarter, including Cornerstone Investment Partners LLC.
How do I buy shares of Compugen?
Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Compugen's stock price today?
One share of CGEN stock can currently be purchased for approximately $3.14.
How big of a company is Compugen?
Compugen has a market capitalization of $148.24 million and generates $710,000.00 in revenue each year. The biotechnology company earns $-37,060,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Compugen employs 101 workers across the globe.
What is Compugen's official website?
How can I contact Compugen?
Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]
MarketBeat Community Rating for Compugen (NASDAQ CGEN)
MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe CGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
